Pharmacotherapy of first-episode psychosis

Bibliography

• POWER P, MCGORRY PD: Initial assessment in first-episode psychosis. In:The Recognition and Management of early Psychosis. A preventive Approach, McGorry PD, Jackson HJ (Eds),Cambridge University Press, UK (1999):155–184.
   Google Scholar
• NORDENTOFT M, JEPPESEN P,ABEL M: Suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis. One-year follow-up of a randomised controlled trial. OPUS study. Br. I Psychiatry (2002) 43:98–106.
   Google Scholar
• SAND OR A, COURTENAY K: First-episode psychosis. Patients must be asked about suicidal ideation and substance misuse. BMJ(2002) 324(7343):976.
   Google Scholar
• BIRCHWOOD M, TODD P, JACKSON C: Early intervention inpsychosis. The critical period hypothesis. Br. J. Psychiatry (1998) 172(33):53–59.
   PubMedGoogle Scholar
• GUT-FAYAND A, DERVAUX A, OLIE JP, LOO H, POIRIER ME KREBS MO: Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity. Psychiatry Res. (2001) 102(1):65–72.
   PubMed Web of Science ®Google Scholar
• JOHNSTONE EC, CROW TJ, JOHNSON AL, MACMILLAN JF: The Northwick Park Study of first-episodes of schizophrenia I. Presentation of the illness and problems relating to admission. Br. J. Psychiatry (1986) 148:115–120.
   Google Scholar
• FENNIG S, BROMET E, JANDORF L: Differences in clinical characteristics of first-admission psychotic depression. Am. J. Psychiatry(1993) 150(11):1734–1736.
   PubMed Web of Science ®Google Scholar
• LAMBERT M, CONUS P, EIDE P, WARD J, YUEN HP, MCGORRY PD: Treatment of early psychosis with olanzapine or risperidone (TEPOR study): methodology and first results of a medical record study in 786 first-episode psychosispatients treated at early psychosisprevention and intervention centre (EPPIC)between 1998 — 2000. Schizophr. Res. (2002) 53\(Suppl. 3):B66.
   Google Scholar
• MATTANAH JJ, BECKER DE LEVY KN, EDELL WS, MCGLASHAN TH: Diagnostic stability in adolescents followed up 2 years after hospitalization. Am. J. Psychiatry (1995) 152(6):889–894.
   PubMed Web of Science ®Google Scholar
• STRAKOWSKI SM, TOHEN M, STOLL AL et al.: Comorbidity in psychosis at first hospitalization. Am. j Psychiatry (1993) 150(5):752–757.
   PubMed Web of Science ®Google Scholar
• MCGORRY PD, COPOLOV DL, SINGH BS: Royal park multidiagnostic instrument for psychosis: Part I. Rationale and review. Schizophr. Bull. (1990) 16(3):501–515.
   PubMed Web of Science ®Google Scholar
• MCGORRY PD, SINGH BS,COPOLOV DL, KAPLAN I, DOSSETOR CR, VAN RIEL RJ:Royal park multidiagnostic instrument forpsychosis: part II: development, reliability,and validity. Schizophr. Bull. (1990) 16(3):517–536.
   PubMed Web of Science ®Google Scholar
• SPITZER RL, WILLIAMS JB,GIBBON M, FIRST MB: The structuredclinical interview for DSM-III-R (SCID)I: history, rationale, and description. Arch. Gen. Psychiatry(1992) 49(8):624–629.
   PubMed Web of Science ®Google Scholar
• Schedules for clinical assessment in neuropsychiatry. WHO, SCAN. World Health Organization, Division of Mental Health, Geneva (1992).
   Google Scholar
• Early Psychosis Prevention and Intervention Group. Psychoeducation in early psychosis. University of Melbourne Press, Melbourne Australia (1998).
   Google Scholar
• DILLING H MOMBOUR W, SCHMIDT GH: International classification of psychotic disorders ICD-10. Hans Huber, Bern Gottingen, Toronto, Canada (1991).
   Google Scholar
• Diagnostic Criteria from DSM-IV. Washington, American Psychiatric Association. American Psychiatric Press (1994).
   Google Scholar
• ADDINGTON J, ADDINGTON D: Cognitive functioning in first-episode schizophrenia. j Psychiatry Neurosci (2002) 27(3):188–192.
   PubMed Web of Science ®Google Scholar
• BILDER RM, GOLDMAN RS, ROBINSON D etal.: Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. J. Psychiatry (2000) 157(4):549–559.
   Google Scholar
• •This study has shown that first-episode at the initial presentation already have severe cognitive deficits, especially in memory, attention span and executive functioning. These results are important for early recognition, early intervention and adaptation of treatment (see also refs [18, 20–221).
   Google Scholar
• FRITS S, SUNDET K, RUND BR, VAGLUM P, MCGLASHAN TH: Neurocognitive dimensions characterising patients with first-episode psychosis. Br. J. Psychiatry (2002) 43:85–90.
   Google Scholar
• RILEY EM, MCGOVERN D,MOCKLER D et al: Neuropsychological functioning in first-episode psychosis-evidence of specific deficits. Schizophr. Res. (2000) 43(1):47–55.
   PubMed Web of Science ®Google Scholar
• SAYKIN AJ, SHTASEL DL, GUR RE et al.: Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch. Gen Psychiatry (1994) 51(2):124–131.
   PubMed Web of Science ®Google Scholar
• ROBINSON DG, WOERNER MG, ALVIR JM, BILDER RM,HINRICHSEN GA, LIEBERMAN JA: Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr. Res. (2002) 57(2-3):209–219.
   PubMed Web of Science ®Google Scholar
• MORITZ S, KRAUSZ M, GOTTWALZ E, LAMBERT M, PERRO C, NABER D: Cognitive dysfunctions at baseline predicts symptomatic one year outcome in first-episode schizophrenics. Psychopathology (2000) 33:48–51.
   PubMed Web of Science ®Google Scholar
• BUHLER B, HAMBRECHT M, LOFFLER W, AN DER HEIDEN W, HAFNER H: Precipitation and determination of the onset and course of schizophrenia by substance abuse - a retrospective and prospective study of 232 population-based first illness episodes. Schizophr. Res. (2002) 54(3):243–251.
   PubMed Web of Science ®Google Scholar
• ADDINGTON D, ADDINGTON J, PATTEN S: Depression in people with first-episode schizophrenia. Br j Psychiatry (1998) 172(33):90–92.
   PubMedGoogle Scholar
• KOREEN AR, SIRIS SG, CHAKOS M, ALVIR J, MAYERHOFF D,LIEBERMAN J: Depression in first-episodeschizophrenia. Am. j Psychiatry (1993) 150(11):1643–1648.
   PubMed Web of Science ®Google Scholar
• WASSINK TH, FLAUM M,NOPOULOS P, ANDREASEN NC: Prevalence of depressive symptoms early in the course of schizophrenia. Am. J. Psychiatry (1999) 156(2):315–316.
   PubMed Web of Science ®Google Scholar
• •This study assessed the prevalence (up to 35%) of depressive symptoms in first-episode schizophrenia showing that depression is an important co-current syndrome even at the first presentation (see also refs 126,271).
   Google Scholar
• MCGORRY PD, CHANEN A, MCCARTHY E, VAN RIEL R, MCKENZIE D, SINGH BS: Post-traumatic stress disorder following recent-onset psychosis. An unrecognized postpsychotic syndrome. Nerv. Merit. Dis. (1991) 179(5):253–258.
   PubMed Web of Science ®Google Scholar
• EDWARDS J, MCGORRY PD: Implementing early intervention in psychosis. Martin Dunitz Publisher (2002).
   Google Scholar
• •This book provides an excellent overview about current concepts and service requirements in the treatment in early psychosis. Its includes actual standards of care and comprise research overviews as well as developments and experiences ofthe Early Psychosis Prevention and Intervention Centre in Melbourne Australia (see also ref [1381).
   Google Scholar
• FITZGERALD P, KULKARNI J: Home-oriented management programme for people with early psychosis. Br. I Psychiatry (1998) 171(Suppl.):39–44.
   Google Scholar
• MCGORRY PD, EDWARDS J, MIHALOPOULOS C: EPPIC: an evolving system of early detection and optimal management. Schizophr. Bull. (1996) 22:305–322.
   PubMed Web of Science ®Google Scholar
• MCGORRY PD, KILLACKEY E, ELKINS K, LAMBERT M, LAMBERT T: Summary of the clinical practice guidelines for the treatment of schizophrenia.The Schizophrenia Clinical Guidelines Development Team. Australasian Psychiatry (Submitted).
   Google Scholar
• DE HAAN L, VAN RAAIJ B, VAN DEN BERG R: Preferences for treatment during a first psychotic episode. Eur. Psychiatry (2001) 16(2):83–89.
   PubMed Web of Science ®Google Scholar
• Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. National Institute for Clinical Excellence (NICE). Clinical Guideline 1, National Collaborating Centre for Mental Health (2002).
   Google Scholar
• ZIPURSKY RB: Optimal pharmacologic management of the first-episode of schizophrenia. In: The early stages of schizophrenia, Kapur S, Zipursky RB (Eds), HarperCollins, NY, USA (2001).
   Google Scholar
• HARRIGAN SM, MCGORRY PD, KRSTEV H: Does treatment delay in first-episode psychosis really matter? Psycho]. Med (2003) 33(1):97–110.
   Web of Science ®Google Scholar
• MALLA AK, NORMAN RM, MANCHANDA R etal.: One year outcome in first-episode psychosis: influence of DUP and other predictors. Schizophr. Res. (2002) 54(3):231–242.
   Google Scholar
• BALDESSARINI R, COHEN B, TEICHER M: Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch. Gen. Psychiatry (1988) 45:79–91.
   PubMed Web of Science ®Google Scholar
• LIEBERMAN J, JODY D, GEISLER S, VITAL-HERNE J, ALVIR JM, WALSLEBEN J, WOERNER MG: Treatment outcome of first-episode schizophrenia. Psychopharmacol Bull. (1989) 25(1):92–96.
   PubMedGoogle Scholar
• LIEBERMAN J, JODY D, GEISLER S et al: Time course and biologic correlates oftreatment response in first-episode schizophrenia. Arch. Gen. Psychiatry (1993) 50(5)369–376.
   Google Scholar
• The Scottish First-Episode Schizophrenia Study II: Treatment: pimozide versus flupenthixol. The Scottish Schizophrenia Research Group. Br j. Psychiatry (1987) 150:334–338.
   Google Scholar
• MCEVOY JP, HOGARTY GE, STEINGARD S: Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch. Gen. Psychiatry (1991) 48(8):739–745.
   Google Scholar
• ZHANG-WONG J, ZIPURSKY RB, BEISER M, BEAN G: Optimal haloperidol dosage in first-episode psychosis. Carr J. Psychiatry (1999) 44(2):164–167.
   PubMed Web of Science ®Google Scholar
• •After studies from Baldessarirti 1988 and McEvoy 1991, the authors focused on the optimal haloperidol dose for a sufficient response in first-episode psychosis showing that higher doses are correlated with a lower response rate compared to low doses (see also refs [39-43,46–49,63,64,711).
   Google Scholar
• KAY SR, OPLER LA,LINDENMAYER JP: Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. (1988) 23(1):99–110.
   PubMed Web of Science ®Google Scholar
• OOSTHUIZEN P, EMSLEY RA, TURNER J, KEYTER N: Determining the optimal dose of haloperidol in first-episode psychosis. j. Psychopharmacol (2001) 15(4):251–255.
   PubMed Web of Science ®Google Scholar
• MERLO MC, HOFER H, GEKLE W et al: Risperidone, 2 mg/d vs 4 mg/d, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. j. CM]. Psychiatry (2002) 63(10):885–891.
   Google Scholar
• YAP HL, MAHENDRAN R, LIM D et al.: Risperidone in the treatment of first-episode psychosis. Singapore Med. 1 (2001) 42(4):170–173.
   Google Scholar
• MCGORRY PD: Recommended haloperidol and risperidone doses in first-episode psychosis. I OM. Psychiatry (1999) 60(11):794–795.
   Google Scholar
• GUTIERREZ FRAILE M, SEGARRA ECHEVARRIA R, GONZALEZ-PINTO ARRILLAGA A, MARTINEZJUN QUERA G: Risperidone in the early treatment of first-episode psychosis: a two-year follow-up study. Actas Esp. Psiquiatr (2002) 30(3):142–152.
   PubMedGoogle Scholar
• SANGER TM, LIEBERMAN JA, TOHEN M, GRUNDY S, BEASLEY C Jr, TOLLEFSON GD: Olanzapine versus haloperidol treatment in first-episode psychosis. Am. J. Psychiatry (1999) 156(1):79–87.
   PubMed Web of Science ®Google Scholar
• GOOD KP, KISS I, BUITEMAN C et al.: Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis. Br. I Psychiatry (2002) 43(Suppl.):S45–S49.
   Google Scholar
• NABER D, LAMBERT M, KRAUSZ M, HAASEN C, PICKAR D: Atypical neuroleptic s in the treatment of schizophrenic patients 2ri edit under special consideration of atypical antipsychotics in kids- and youth psychiatry. UNI-MED publisher (2002).
   Google Scholar
• AGUILAR EJ, KESHAVAN MS, MARTINEZ-QUILES MD, HERNANDEZ J,GOMEZ-BENEYTO M,SCHOOLER NR: Predictors of acute dystonia in first-episode psychotic patients. Am. j. Psychiatry (1994) 151(12):1819–1821.
   PubMedGoogle Scholar
• LAMBERT M: Treatment non-response in schizophrenia. In: Atypical neuroleptic s in the treatment of schizophrenic patients, 2ri edit, Naber D, Lambert M, Krausz M, Haasen C, Pickar D, UNI-MED (2002):81–100.
   Google Scholar
• RICHARDSON MA, HAUGLAND G, CRAIG TJ: Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. Am. J. Psychiatry (1991) 148(10):1322–1328.
   PubMed Web of Science ®Google Scholar
• DUKE PJ, PANTELIS C, BARNES TR: South Westminster schizophrenia survey. Alcohol use and its relationship to symptoms, tardive dyskinesia and illness onset. Br. J. Psychiatry (1994) 164(5):630–636.
   Google Scholar
• CHOUINARD G, ANNABLE L, ROSS-CHOUINARD A, MERCIER P: A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. j. CM]. Psychopharmacol. (1988) 8\(Suppl. 4):21–26.
   Google Scholar
• ROBINSON D, WOERNER M, ALVIR J et al.: Predictors of treatment response from a first-episode of schizophrenia of schizoaffective disorder. Am. j. Psychiatry (1999) 156:544–549.
   PubMed Web of Science ®Google Scholar
• •This article examined relapse after response to a first-episode of schizophrenia or schizoaffective disorder showing thatthere is a high rate of relapse within 5 years of recovery from a first-episode and that this risk is diminished by maintenance antipsychotic drug treatment (see also refs [26,271).
   Google Scholar
• FENTON WS, BLYLER C, HEINSSEN R: Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr. Bull. (1997) 23:637–651.
   PubMed Web of Science ®Google Scholar
• •Compliance is a very important issue in psychotic patients. Determinants, influences of non-compliance on the course of illness and guidelines for dealing with this problem are reviewed in this article (see also refs [61,761).
   Google Scholar
• KAMPMAN 0, LAIPPALA P, VAANANEN J et al.: Indicators of medication compliance in first-episode psychosis. Psychiatry Res. (2002) 110 (1):39–48.
   Google Scholar
• MCEVOY JP, SCHEIFLER PL, FRANCES A: The expert consensus guideline series: treatment of schizophrenia.OM. Psychiatry (1999) 60\(Suppl. 10:3–80.
   Google Scholar
• KAPUR S, ZIPURSKY R, JONES C, REMINGTON G, HOULE S: Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. I Psychiatry (2000) 157(4):514–520.
   PubMed Web of Science ®Google Scholar
• KAPUR S, ZIPURSKY R, ROY P et al: The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology (1997) 131(2):148–152.
   PubMed Web of Science ®Google Scholar
• JANICAK PG, KECK PE Jr, DAVIS JM et al.: A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder. Psychopharmacol. (2001) 21(4):360–368.
   Web of Science ®Google Scholar
• STONE CK, GARVER DL, GRIFFITH J et al.: Further evidence of s dose response threshold for haloperidol in psychosis. Am. j. Psychiatry (1995) 152:1210–1212.
   PubMed Web of Science ®Google Scholar
• LEUCHT S, PITSCHEL-WALZ G, ABRAHAM D, TUSSLING W: Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res. (1999) 35(1):51–68.
   Google Scholar
• LEUCHT S, PITSCHEL-WALZ G, ENGEL RR, TUSSLING W: Amisulpride, an unusual 'atypical' antipsychotic: a meta-analysis of randomized controlled trials. Am. J. Psychiatry (2002) 159(2):180–190.
   PubMed Web of Science ®Google Scholar
• EMSLEY RA: Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr. Bull. (1999) 25(4)721–729.
   Google Scholar
• KESHAVAN MS, SCHOOLER NR, SWEENEY JA, HAAS GL,PETTEGREW JW: Research and treatment strategies in first-episode psychoses. The Pittsburgh experience. Br J. Psychiatry (1998) 172(33):60–65.
   Google Scholar
• KONTAXAKIS VP, HAVAKI-KONTAXAKI BJ, STAMOULI SS, CHRISTODOULOU GN: Optimal risperidone dose in drug-naive, first-episode schizophrenia. Am. J. Psychiatry (2000) 157(7):1178–1179.
   PubMed Web of Science ®Google Scholar
• KOPALA LC, FREDRIKSON D, GOOD KP HONER WG: Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone. Biol. Psychiatry (1996) 39(4):296–298.
   PubMed Web of Science ®Google Scholar
• MALLA AK, NORMAN RIVI, SCHOLTEN DJ, ZIRUL S,KOTTEDA V: A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic. j Clin. Psychiatry (2001) 62(3):179–184.
   PubMed Web of Science ®Google Scholar
• ALVAREZ E, BOBES J, GOMEZ JC et al.: Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study. Eur. Neuropsychopharmacol. (2003) 13(1):39–48.
   PubMed Web of Science ®Google Scholar
• HELLEWELL JS: Patients subjective experiences of antipsychotics: clinical relevance. CNS Drugs (2002) 16(7):457–471.
   PubMed Web of Science ®Google Scholar
• YOUNG J, ZONANA H, SHEPLER L: Medication non-compliance in schizophrenia: codification and update. Bull. Am. Acad. Psychiatry Law (1986) 14:105–122.
   PubMedGoogle Scholar
• BOWDEN CL, BRUGGER AM, SWANN AC et al.: Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA (1994) 271(12):918–924.
   PubMed Web of Science ®Google Scholar
• KELLEHER JP, CENTORRINO F, ALBERT MJ, BALDESSARINI RJ: Advances in atypical antipsychotics for thetreatment of schizophrenia: new formulations and new agents. CNS Drugs (2002) 16(4):249–261.
   PubMed Web of Science ®Google Scholar
• CALABRESE JR, SHELTON MD, RAPPORT DJ, KIMMEL SE: Bipolar disorders and the effectiveness of novel anticonvulsants. I Clin. Psychiatry (2002) 63\(Suppl. 3):5–9.
   Google Scholar
• GLICK RL, GHAEMI SN: The emergency treatment of depression complicated by psychosis or agitation. J. Clin. Psychiatry (2000) 61\(Supp1.14):43–48.
   Google Scholar
• MCELROY SL, KECK PE JR,POPE HG Jr, HUDSON JI: Valproate in the treatment of bipolar disorder: literature review and clinical guidelines.v ?Clin. Psychopharmacol (1992) 12\(Suppl. 1):542–552.
   Google Scholar
• MCELROY SL, KECK PE Jr,STRAKOWSKI SM: An overview of the treatment of schizoaffective disorder. ?Clin. Psychiatry (1999) 60\(Suppl. 5):16–21.
   Google Scholar
• MCELROY SL, KECK PE Jr:Pharmacologic agents for the treatment of acute bipolar mania. Bid. Psychiatry (2000) 48(6):539–557.
   PubMed Web of Science ®Google Scholar
• •Pharmacological treatment ofschizoaffective disorder has not been well studied. The authors review studies of pharmacological agents, present pharmacological treatment guidelines for the disorder (see also refs [88, 89, 96, 102]).
   Google Scholar
• CONUS P, MCGORRY PD: First-episodemania: a neglected priority for early intervention. Aust. NZ J. Psychiatry (2002) 36:158–172.
   PubMed Web of Science ®Google Scholar
• •This article gives an excellent overview on first-episode mania showing that when functional, as well as symptomatic variables are considered, outcome of these patients is not as good as formerly believed and that specialised services, as well as intensive research, is needed to improve outcome of these patients.
   Google Scholar
• OKUMA T, YAMASHITA I,TAKAHASHI R et al: Clinical efficacy of carbamazepine in affective, schizoaffective, and schizophrenic disorders. Pharmacupsychiatry (1989) 22(2):47–53.
   PubMed Web of Science ®Google Scholar
• Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am. J. Psychiatry (2000) 157(4):1–45.
   Google Scholar
• •Gives an important overview of the treatment of patients with depressivedisorder (see also refs [104, 105, 107–109,111,114]).
   Google Scholar
• Practice guideline for the treatment ofpatients with bipolar disorder (revision). American Psychiatric Association. Am. J. Psychiatry (2002) 159(4):4–50.
   Google Scholar
• •Gives an important overview of the treatment of patients with bipolar disorder (see also refs [81, 83, 89-91,93-95,97-99,102,1061).
   Google Scholar
• KECK PE Jr, MCELROY SL, STRAKOWSKI SM: Schizoaffective disorder: role of atypical antipsychotics. Schizophr. Res. (1999) 35:S5–S12.
   Web of Science ®Google Scholar
• MILLER DS, LAKSHMI NY, LAM RW: Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood-stabilizers in the treatment of acute mania. Clin. Psychiatry (2001) 62:975–980.
   PubMed Web of Science ®Google Scholar
• STRAKOWSKI SM, DELBELLO MP, ADLER CM: Comparative efficacy and tolerability of drug treatments for bipolar disorder. CNS Drugs (2001) 15(9):701–718.
   PubMed Web of Science ®Google Scholar
• SUPPES T, DENNEHY EB, SWANN AC eta].: Report of the Texas consensus conference panel on medication treatment of bipolar disorder 2000.1 Clin. Psychiatry (2002) 63(4):288–299.
   Google Scholar
• YATHAM LN: Mood stabilization and the role of antipsychotics. ?Clin. Psychopharmacol (2002) 17\(Suppl. 3):21–27.
   Google Scholar
• FRYE MA, KETTER TA,ALTSHULER LL et al: Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. J. Affect. Disorder (1998) 48(2-3):91–104.
   PubMed Web of Science ®Google Scholar
• SANGER TM, GRUNDY SL, GIBSON PJ, NAMJOSHI MA, GREANEY MG, TOHEN MF: Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. Clin. Psychiatry (2001) 62(4):273–281.
   PubMed Web of Science ®Google Scholar
• TOHEN M, SANGER TM,MCELROY SL et al.: Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am. J. Psychiatry (1999) 156(5):702–709.
   Google Scholar
• TOHEN M, ZHANG F, KECK PE etal.: Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. J. Affect. Disorder (2001) 67(1–3):133–140.
   Google Scholar
• TOHEN M, CHENGAPPA KN, SUPPES T et al.: Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partiallynonresponsive to valproate or lithium monotherapy. Arch. Gen. Psychiatry (2002) 59(1):62–69.
   PubMed Web of Science ®Google Scholar
• TOHEN M, BAKER RW,ALTSHULER LL et al.: Olanzapine versus divalproex in the treatment of acute mania. Am. J. Psychiatry (2002) 159(6):1011–1017.
   Google Scholar
• VIETA E, REINARES M, CORBELLA B et al: Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. j Chi]. Psychopharmacol. (2001) 21(5):469–473.
   PubMed Web of Science ®Google Scholar
• JANICEK PG, JAVAID JI, SHARMA RP et al: A two-phase, double-blind randomized study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders. Acta Psychiatr. Scam/. (1997) 95:343–350.
   PubMed Web of Science ®Google Scholar
• SACHS GS, GROSSMAN F,GHAEMI SN, OKAMOTO A, BOWDEN CL: Combination of a mood-stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am. I Psychiatry (2002) 159(7):1146–1154.
   PubMed Web of Science ®Google Scholar
• VIETA E, GOIKOLEA JM,CORBELLA B et al.: Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. Chi]. Psychiatry (2001) 62(10):818–825.
   Google Scholar
• BROWN ES, NEJTEK VA, PERANTIE DC, BOBADILLA L: Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disorder (2002) 4(6):406–411.
   PubMed Web of Science ®Google Scholar
• ROCCA P, MARCHIARO L, RASETTI R, RIVOIRA E, BOGETTO F: A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes. Psychiatry Res. (2002) 112(2):145–152.
   PubMed Web of Science ®Google Scholar
• ROCCA P, FONZO V, RAVIZZA L et al.: A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. j Affect. Disord. (2002) 70(3):313–317.
   PubMed Web of Science ®Google Scholar
• VIETA E, PARRAMON G, PADRELL E et al: Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord. (2002) 4(5):335–340.
   PubMed Web of Science ®Google Scholar
• CASSANO GB, JORI MC: Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel groupstudy. BIL Chi]. Psychopharmacol. (2002) 17(1):27–32.
   Google Scholar
• SAJATOVIC M, MULLEN JA,SWEITZER DE: Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis.Chi]. Psychiatry (2002) 63(12):1156–1163.
   Google Scholar
• FRYE MA, KETTER TA, KIMBRELL TA etal.: A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders.Chi]. Psychopharmacol. (2000) 22:241–247.
   Google Scholar
• ICHIM L, BERK M, BROOKS: Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Ann. Clin. Psychiatry (2000) 12:5–10.
   PubMedGoogle Scholar
• MENDLEWICZ J: Optimising antidepressant use in clinical practice: towards criteria for antidepressant selection. Br. I Psychiatry (2001) 42:S1–S3.
   Google Scholar
• MATTHEWS JD, BOTTONARI KA, POLANIA LM et al.: An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses.Chi]. Psychiatry (2002) 63 (12):1164-1170.
   Google Scholar
• MYERS JE, THASE ME: Risperidone: review of its therapeutic utility in depression. Psychopharmacol. Bull. (2001) 35(4):109–129.
   PubMedGoogle Scholar
• ADLI M, BERGHOFER A, LINDEN M et al.: Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study.Chi]. Psychiatry (2002) 63(9):782–790.
   Google Scholar
• EBERT D, JASPERT A, MURATA H, KASCHKA WP: Initial lithium augmentation improves the antidepressant effects of standard TCA treatment in non-resistant depressed patients.Psychopharmacology (1995) 118(2):223–225.
   PubMed Web of Science ®Google Scholar
• HEIT S, NEMEROFF CB: Lithium augmentation of antidepressants in treatment-refractory depression.Chi]. Psychiatry (1998) 59 (Suppl. 6):28-33; Discussion 34.
   Google Scholar
• DILSAVER SC, SWANN SC, CHEN YW etal.: Treatment of bipolar depression with carbamazepine: results of an open study. Bid. Psychiatry (1996) 40(9):935–937.
   Google Scholar
• LOEBEL AD, LIEBERMAN JA,ALVIR JM, MAYERHOFF DI,GEISLER SH, SZYMANSKI SR: Duration of psychosis and outcome in first-episodeschizophrenia. Am. I Psychiatry (1992) 149(9):1183–1188.
   PubMed Web of Science ®Google Scholar
• CALABRESE JR, DELUCCHI GA: Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am. I Psychiatry (1990) 147(4):431–434.
   PubMed Web of Science ®Google Scholar
• ALLEN MH, CURRIER GW,HUGHES DH, REYES-HARDE M, DOCHERTY JP: The expert consensus guideline series. Treatment of behavioral emergencies. Postgrad. Med. (2001) (Spec. No.):1-88; Quiz 89–90 (Review).
   Google Scholar
• •Provides an overview and treatment guidelines of psychiatric emergencies. These recommendations are important, especially to offer appropriate interventions to prevent traumatic experiences for patients and caregivers.
   Google Scholar
• BREIER A, MEEHAN K, BIRKETT M et al.: A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch. Gen. Psychiatry (2002) 59(5):441–448.
   PubMed Web of Science ®Google Scholar
• •This study assessed efficacy and tolerability of intramuscular formulation of olanzapine for treating acute agitation in patients with schizophrenia. This study has shown that intramuscular olanzapine 2.5-10.0 mg per injection exhibits a dose-response relationship and demonstrates a favourable safety profile compared to haloperidol (see also references 1122-120.
   Google Scholar
• JONES B, TAYLOR CC, MEEHAN K: The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. I Chi]. Psychiatry (2001) 62\(Suppl. 2):22–24.
   Google Scholar
• MEEHAN K, ZHANG F, DAVID S et al.: A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania.Chi]. Psychopharmacol. (2001) 21(4):389–397.
   Google Scholar
• WRIGHT P, BIRKETT M, DAVID SR et al.: Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am. J. Psychiatry (2001) 158(7):1149–1151.
   PubMed Web of Science ®Google Scholar
• BROOK S: A pilot study of intramuscular ziprasidone in the short-term treatment of patients with acute exacerbation ofschizophrenia. Hum. Psychopharmacol. (2000) 15(7):521–524.
   Google Scholar
• LESEM MD, ZAJECKA JM, SWIFT RH, REEVES KR, HARRIGAN EP: Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients.Gbh. Psychiatry(2001) 62(1):12–18.
   Google Scholar
• TANDON R, HARRIGAN E, ZORN SH: Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. j Serotortin Research (1997) 4:159–177.
   Google Scholar
• EDWARDS J, MCGORRY PD, WADDELL FM, HARRIGAN SM: Enduring negative symptoms in first-episode psychosis: comparison of six methods using follow-up data.Schizophr. Res. (1999) 40(2):147–158.
   Google Scholar
• •A study of negative symptoms in first-episode psychosis. The negative symptom group had significantly lower scores on quality of life, poorer premorbid adjustment, and longer durations of prodrome and untreated psychosis showing that intensive research is needed in this field.
   Google Scholar
• HO BC, NOPOULOS E FLAUM M, ARNDT S, ANDREASEN NC: Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am. J. Psychiatry (1998) 155(9):1196–1201.
   PubMed Web of Science ®Google Scholar
• LINSZEN D, DINGEMANS P, LENIOR M: Early intervention and a five year follow up in young adults with a short duration of untreated psychosis: ethical implications. Schizophr. Res. (2001) 51(1):55–61.
   PubMed Web of Science ®Google Scholar
• WATT DC, KATZ K, SHEPHERD M: The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment. Psycho]. Med. (1993) 13:663–670.
   Google Scholar
• WESTERMEYER JF, HARROW M: Prognosis and outcome using broad (DSM-II) and narrow (DSM-III) concepts of schizophrenia. Schizophr. Bull. (1984) 10:624–637.
   PubMed Web of Science ®Google Scholar
• BRAMBILLA P, BARALE ECAVERZASI E, TOGNONI G,BARBUI C: Clozapine-treated subjects with treatment-resistant schizophrenia: a systematic review of experimental and observational studies.Int. Chit. Psychopharmacol. (2002) 17(4):189–195.
   Google Scholar
• LAMBERT M, CONUS P, EIDE P, KAROW A, KRAUSZ M, NABER D: Impact of present and past side effects on the attitude towards typical antipsychotic treatment. Eur. Psychiatry (Submitted).
   Google Scholar
• SZYMANSKI SR, CANNON TD, GALLACHER E ERWIN RJ, GUR RE: Course of treatment response in first-episode and chronic schizophrenia. Am. J. Psychiatry (1996) 153(4):519–525.
   PubMed Web of Science ®Google Scholar
• CONLEY RR: Risperidone side effects. Chit. Psychiatry (2000) 61\(Suppl. 8):52–61.
   Google Scholar
• SEVY S, ROBINSON DG,HOLLOWAY S et al: Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr. Scand. (2001) 104(5):367–374.
   PubMed Web of Science ®Google Scholar
• Systematic Treatment of Persistent Psychosis (STOPP). A psychological approach to facilitating recovery in young people with first-episode psychosis. Herrmann-Doig T, Maude D, Edwards J (Eds), Martin Dunitz, UK (2003).
   Google Scholar
• BREIER A, MALHORTA A,TUNG-PING S et al.: Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am. j Psychiatry (1999) 156:294–298.
   Google Scholar
• LINDENMAYER JP, VOLAVKA J, LIEBERMAN J et al.: Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. I Chu. Psychopharmacol (2001) 21(4):448–453.
   Web of Science ®Google Scholar
• TOLLEFSON GD, BIRKETT MA, KIESLER GM, WOOD AJ: Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.Biol. Psychiatry (2001) 49(1):52–63.
   Google Scholar
• ZHANG XY, ZHOU DE CAO LY, ZHANGPY, WU GY, SHEN YC: Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. Int. Chit. Psychopharmacol (2001) 16(6):325–330.
   PubMed Web of Science ®Google Scholar
• MOLLER HJ: Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. (2001) 251(5):217–224.
   PubMed Web of Science ®Google Scholar
• NABER D, LAMBERT M: Amisulpride: a safe and effective option for the long-term treatment of patients with schizophrenia. Chu. Psych. Practice (In Press).
   Google Scholar
• NARENDRAN R, YOUNG CM, VALENTI AM, PRISTACH CA, PATO MT, GRACE JJ: Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study.Chu. Psychiatry (2001) 62(7):509–516.
   Google Scholar
• PEUSKENS J, SIENAERT M,DE HERT M: Sexual dysfunction: the unspoken side-effect of antipsychotics. Eur. Psychiatry (1998) 13\(Suppl. 1):23–30.
   Google Scholar
• TAYLOR DM, DUNCAN-MCCONNELL D: Refractory schizophrenia and atypical antipsychotics. Psychopharmacol (2000) 14(4):409–418.
   Web of Science ®Google Scholar
• LANE HY, CHANG YC, CHANG WH, LIN SK, TSENG YT, JANN MW: Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. j Chu. Psychiatry (1999) 60(1):36–40.
   PubMed Web of Science ®Google Scholar
• KRONIG M, MUNNE R, SZYMANSKI S et al.: Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am. j Psychiatry (1995) 152:179–182.
   PubMed Web of Science ®Google Scholar
• LLORCA PM, CHEREAU I, BAYLE FJ, LANCON C: Tardive dyskinesias and antipsychotics: a review. Eur. Psychiatry (2002) 17(3):129–138.
   PubMed Web of Science ®Google Scholar
• POTKIN SG, BERA R,GULASEKARAM B et al.: Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. j Clin. Psychiatry (1994) 55:133–136.
   Google Scholar
• SPINA E, AVENOSO A, FACCIOLA G et al.: Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (2000) 148:83–89.
   PubMed Web of Science ®Google Scholar
• VAN DER ZWAAG C, MCGEE M, MCEVOY J, FREUDENREICH 0, WILSON W, COOPER T: Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am. j Psychiatry (1996) 153:1579–1584.
   PubMed Web of Science ®Google Scholar
• CASEY D: Motor and mental aspects of acute extrapyramidal syndromes. Acta Psychiatc Scand. (1994) 89 (Suppl. 380) :14–20.
   Google Scholar
• WHITWORTH AB,FLEISCHHACKER W: Adverse effects of antipsychotic drugs. Int. OM. Psychopharmacol (1995) 9 (Suppl. 5):21–27.
   Google Scholar
• REMINGTON G, KAPUR S,ZIPURSKY R: Pharmacotherapy of first-epsiode schizophrenia. Br j Psychiatry (1998) 172\(Suppl. 33):66–70.
   Google Scholar
• FRIEDMAN JH: Atypical antipsychotics in the EPS-vulnerable patient. Psychorieuroendocrinology (2003) 28\(Suppl. 1):39–51.
   Google Scholar
• LAMBERT M: Adverse neuroleptic effects and their treatment. In: Atypical rieuroleptics in the treatment of schizophrenic patients, 2m edri, Naber D, Lambert M, Krausz M, Haasen C, Pickar D (Eds), UNI-MED publisher, Germany (2002):101–130.
   Google Scholar
• ARATO M, O'CONNOR R,MELTZER HY: A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the ziprasidone extended use in schizophrenia (ZEUS) study. OM. Psychopharmacol (2002) 17(5):207–215.
   Web of Science ®Google Scholar
• GOODNICKPJ, JERRY JM: Aripiprazole: profile on efficacy and safety. Expert Opiri. Pharmacother. (2002) 3(12):1773–1781.
   PubMedGoogle Scholar
• VAN PUTTEN T, MAY P, MARDER SR, WITTMANN L: Subjective response to antipsychotic drugs. Arch. Gen. Psychiatry (1981) 38:187–190.
   PubMed Web of Science ®Google Scholar
• KRAUSZ M, MORITZ SH, NABER D, LAMBERT M, ANDRESEN B: Neuroleptic-induced extrapyramidal symptoms are accompanied by cognitive dysfunction in schizophrenia. Eur. Psychiatry (1999) 14(2):84–88.
   PubMed Web of Science ®Google Scholar
• SPOHN HE, STRAUSS ME: Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. Abriorm. Psychology (1989) 98:367–380.
   PubMed Web of Science ®Google Scholar
• BARNES TRE, MCPHILLIPS MA: Antipsychotic-induced extrapyramidal symptoms: role of anticholinergic drugs in treatment. CNS Drugs (1996) 6:315–30.
   Web of Science ®Google Scholar
• STANILLA JK AND SIMPSON GM: Drugs to treat extrapyramidal side effects, In: The American psychiatric press textbook of psychopharmacology, Schatzberg A,Nemeroff C (Eds), American Psychiatric Press,WA, USA (1995):281–299.
   Google Scholar
• GLAZER WM: Review of incidence studies of tardive dyskinesia associated with typicalantipsychotics. j Clin. Psychiatry (2000) 61 (Suppl. 4):15–20.
   Google Scholar
• GLAZER WM: Expected incidence of tardive dyskinesia associated with atypical antipsychotics. j OM. Psychiatry (2000) 61 (Suppl. 4):21–26.
   Google Scholar
• LLORCA PM, LANCON C, DISDIER B, FARISSE J, SAPIN C, AUQUIER P: Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations. Psychiatry Neurosci. (2002) 27(1):30–37.
   PubMed Web of Science ®Google Scholar
• TOLLEFSON GD, BEASLEY CM Jr, TAMURA RN, TRAN PV, POTVIN JH: Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am. I Psychiatry (1997) 154(9):1248–1254.
   PubMed Web of Science ®Google Scholar
• JESTE DV, CALIGIURI MP, PAULSEN JS eta].: Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch. Gen. Psychiatry (1995) 52(9):756–765.
   Google Scholar
• KANE JM, WOERNER M, BORENSTEIN M, WEGNER J, LIEBERMAN J: Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull. (1986) 22(1):254–258.
   PubMedGoogle Scholar
• WOERNER MG, ALVIR JM, SALTZ BL, LIEBERMAN JA, KANE JM: Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am. I Psychiatry (1998) 155(11):1521–1528.
   PubMed Web of Science ®Google Scholar
• YASSA R, NAIR N, ISKANDAR H, SCHWARZT G: Factors in the development of severe forms of tardive dyskinesia. Am. I Psychiatry (1990) 147:1156–1163.
   PubMed Web of Science ®Google Scholar
• BERGEN J, KITCHIN R, BERRY G: Predictors of the course of tardive dyskinesia in patients receiving neuroleptics. Biol. Psychiatry (1992) 32(7):580–594.
   PubMed Web of Science ®Google Scholar
• EGAN MF, APUD J, WYATT RJ: Treatment of tardive dyskinesia. Schizophr. Bull. (1997) 23(4):583–609.
   PubMed Web of Science ®Google Scholar
• •A review of literature concerning tardive dyskinesia, showing that despite treatment developments, this disorder remains a significant clinical problem for patients and physicians. The article gives advice for pharmacological interventions (see also refs [166, 167, 169,170–174,176]).
   Google Scholar
• SIMPSON GM: The treatment of tardive dyskinesia and tardive dystonia. Cliri. Psychiatry (2000) 61\(Suppl. 4):39–44.
   Google Scholar
• BARNETT AA: Safety concerns over antipsychotic drug, sertindole. Lancet (1996) 348:256–257.
   Web of Science ®Google Scholar
• FDA Briefing document for Zeldox capsules (Ziprasidone), Pfizer Inc., NY, USA, July 18, (2000):16.
   Google Scholar
• GLASSMAN AH, BIGGER JT Jr: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am. J Psychiatry (2001) 158(11):1774–1782.
   PubMed Web of Science ®Google Scholar
• •Provides a good and actual review of QTc prolongation under various antipsychotics (see also ref [180]).
   Google Scholar
• MELTZER HY, DAVIDSON M, GLASSMAN AH, VIEWEG WV: Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. I OM. Psychiatry (2002) 63 (Suppl. 9):25–29.
   Google Scholar
• BAPTISTA T: Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr. Scarid (1999) 100(1):3–16.
   PubMed Web of Science ®Google Scholar
• GREEN A, PATEL J, GOISMAN R, ALLISON D, BLACKBURN G: Weight gain from novel antipsychotic drugs: need for action. Gen. Hosp. Psychiatry (2000) 22(4):224–235.
   PubMed Web of Science ®Google Scholar
• NASRALLAH H: A review of the effect of atypical antipsychotics on weight. Psychorieuroendocrinology (2003) 28:83–96.
   PubMed Web of Science ®Google Scholar
• •Provides a review of the effect of atypical antipsychotics on weight. The authors concluded that the weight-gain profile of an antipsychotic should be a factor to consider when constructing an algorithm for treatment (see also refs [181, 182, 184–187,189–193,201]).
   Google Scholar
• SUSSMAN N: Review of atypical antipsychotics and weight gain. Clin. Psychiatry (2001) 62\(Suppl. 23):5–12.
   Google Scholar
• BASILE VS, MASELLIS M,MCINTYRE RS, MELTZER HY, LIEBERMAN JA, KENNEDY JL: Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. I OM. Psychiatry (2001) 62\(Suppl. 23):45–66.
   Google Scholar
• MCINTYRE RS, MANCINI DA,BASILE VS: Mechanisms of antipsychotic-induced weight gain. I OM. Psychiatry (2001) 62\(Suppl. 23):23–29.
   Google Scholar
• ARONNE LJ: Epidemiology, morbidity, and treatment of overweight and obesity. OM. Psychiatry (2001) 62\(Suppl. 23):13–22.
   Google Scholar
• NEWMAN SC, BLAND RC: Mortality in a cohort of patients with schizophrenia: a record linkage study. Can. I Psychiatry (1991) 36(4):239–245.
   PubMed Web of Science ®Google Scholar
• ALLISON DB, MENTORE JL, HEO M et al.: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry (1999) 156(11):1686–1696.
   PubMed Web of Science ®Google Scholar
• LEVY E, MARGOLESE HC,CHOUINARD G: Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia. Clin. Psychiatry (2002) 63(11):1045.
   PubMed Web of Science ®Google Scholar
• WIRSHING DA, WIRSHING WC, KYSAR L et al.: Novel antipsychotics: comparison of weight gain liabilities. Clin. Psychiatry (1999) 60(6):358–363.
   PubMed Web of Science ®Google Scholar
• JAMES WP ASTRUP A, FINER N et al.: Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet (2000) 356(9248):2119–2125.
   Google Scholar
• SJOSTROM L, RISSANEN A,ANDERSEN T et al: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet (1998) 352(9123):167–172.
   PubMed Web of Science ®Google Scholar
• SACCHETTI E, GUARNERI L, BRAVI D: H2 antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. Biol. Psychiatry (2000) 48(2):167–168.
   PubMed Web of Science ®Google Scholar
• CARO JJ, WARD A, LEVINTON C, ROBINSON K: The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. Clin. Psychiatry (2002) 63(12):1135–1139.
   PubMed Web of Science ®Google Scholar
• HEDENMALM K, HAGG S, STAHL M, MORTIMER 0, SPIGSET 0: Glucose intolerance with atypical antipsychotics. Drug Safety (2002) 25(15):1107–1116.
   PubMed Web of Science ®Google Scholar
• SERNYAK MJ, LESLIE DL,ALARCON RD, LOS ONCZY ME ROSENHECK R: Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am. J. Psychiatry (2002) 159(4):561–566.
   PubMed Web of Science ®Google Scholar
• DIXON L, WEIDEN P, DELAHANTY J et al.: Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr. Bull. (2000) 26(4):903–912.
   PubMed Web of Science ®Google Scholar
• FLETCHER PJ: Increased food intake in satiated rats induced by the 5-HT antagonists methysergide, metergoline and ritanserin. Psychopharmacology (1988) 96(2):237–242.zoo. GARATTINI S, MENNINI T,SAMANIN R: Reduction of food intake by manipulation of central serotonin. Current experimental results. Br I Psychiatry (1989) 8:S41–S51.
   Google Scholar
• WETTERLING T, MUSSIGBRODT HE: Weight gain: side effect of atypical neuroleptics? I Clin. Psychopharmacol (1999) 19(4):316–321.zoz. WIRSHING DA, SPELLBERG BJ, ERHART SM, MARDER SR, WIRSHING W: Novel antipsychotics and new onset diabetes. Biol. Psychiatry (1998) 44(8):778–783.
   Google Scholar
• BROMEL T, BLUM WE ZIEGLER A et al: Serum leptin levels increase rapidly after initiation of clozapine therapy. Malec. Psychiatry (1998) 3(1):76–80.
   PubMed Web of Science ®Google Scholar
• OSSER DN, NAJARIAN DM, DUFRESNE RL: Olanzapine increases weight and serum triglyceride levels. Clin. Psychiatry (1999) 60(10:767-770.zos. PEUSKENS J, MOLLER HJ, PUECH A: Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur. Neuropsychopharmacol. (2002) 12(4):305–310.
   Google Scholar
• SIGUSCH V: Sexual dysfunctions and their treatment. Thieme Medical Publishers, NY, USA (1997).
   Google Scholar
• BREIER A, HAMILTON SH: Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol. Psychiatry (1999) 45(4):403–411.
   PubMed Web of Science ®Google Scholar
• CONLEY RR, KELLY DL: Management of treatment resistance in schizophrenia. Biol. Psychiatry (2001) 50(11):898–911.zos. HALBREICH U, KINON BJ,GILMORE JA, KAHN LS: Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology (2003) 28\(Suppl. 1):53–67.
   Google Scholar
• REIN W, TURJANSKI S, FAVENNEC-MEIDINGER C: Amisulpride, an atypical antipsychotic - safety profile. In: Xth WPA Congress, Madrid, Spain (1996).
   Google Scholar
• TURRONE E KAPUR S, SEEMAN MV, FLINT AJ: Elevation of prolactin levels byatypical antipsychotics. Am. j Psychiatry (2002) 159(1):133–135.
   PubMed Web of Science ®Google Scholar
• WUDARSKY M, NICOLSON R, HAMBURGER SD et al.: Elevated prolactin in pediatric patients on typical and atypical antipsychotics. I Child Adolesc. Psychopharmacol (1999) 9(4):239–245.
   PubMed Web of Science ®Google Scholar
• DAVID SR, TAYLOR CC, KINON BJ, BREIER A: The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther (2000) 22(9):1085–1096.
   PubMed Web of Science ®Google Scholar
• MEATS P: Quetiapine (Seroquel), an effective and well-tolerated atypical antipsychotic. mt. I Psychiatry Chia. Pic. (1997) 1:231–239.
   Google Scholar
• WEIDEN PJ, NAVEED I, MENDELOWITZ TANDON R, ZIMBROFF DL, ROSS R: Best clinical practice with ziprasidone: update after one year experience. I Psych. Practice (2002) 8:81–98.
   PubMedGoogle Scholar
• VIGUERA AC, BALDESSARINI RJ, HEGARTY JD, VAN KAMMEN DP, TOHEN M: Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch. Gen. Psychiatry (1997) 54(1):49–55.
   PubMed Web of Science ®Google Scholar
• BOSVELD-VAN HAANDEL LJ, SLOOFF CJ, VAN DEN BOSCH RJ: Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments. Acta Psychiam Scam/. (2001) 103(5):335–346.
   PubMed Web of Science ®Google Scholar
• •This article provides a review of evidence-based literature regarding the necessary duration of antipsychotic relapse prevention in schizophrenia and related psychoses.
   Google Scholar
• GITLIN M, NUECHTERLEIN K, SUBOTNIK KL et al: Clinical outcome following neuroleptic discontinuation in Patients with remitted recent-onset schizophrenia. Am. I Psychiatry (2001) 158(10:1835–1842.
   PubMedGoogle Scholar
• WIERSMA D, NIENHUIS FJ,SLOOFF CJ, GIEL R: Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort. Schizophr. Bull. (1998) 24:75-65.zzo.
   Google Scholar
• HOGARTY GE, GOLDBERG SC, SCHOOLER NR, ULRICH RF: Drug and sociotherapy in the aftercare of schizophrenic patients: two year relapse rates. Arch. Gen. Psychiatry (1974) 31:603–608.
   PubMed Web of Science ®Google Scholar
• ZIPURSKY RB: Optimal pharmacologic management of the first-episode of schizophrenia. In: The early stages of schizophrenia. Kapur S, Zipursky RB (Eds), American Psychiatric Publishing Inc. Washington DC, USA (2001).
   Google Scholar